Research

Biomarkers 


Assignment of patients with lung cancer to the variety of available conventional and novel therapeutics such as immunotherapy is currently informed by highly rudimentary data. As a result, predicting response rates to conventional systemic therapy, single or multi-target immunotherapy or combinatorial approaches is difficult and may lead to sub-optimal patient outcomes both regarding response and toxicity. The lab uses next-generation sequencing technology to define how and when, amongst the available armamentarium of systemic therapies, which are optimally utilized by delineating their mechanisms and the contexts within which they perform best.

©2019 by Walsh Lab. Proudly created with Wix.com